Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \>=18 years, either sex, any race.
Eastern Cooperative Oncology group performance status of 0 or 1.
Adequate hematologic, renal, and hepatic organ function and laboratory parameters.
For subjects with MCL:
* Diagnosis of MCL according to the World Health Organization (WHO) criteria.
* Received at least one prior chemotherapeutic regimen, but no more than two regimens including stem cell transplantation..
* Measurable or assessable disease by the Revised Response Criteria for Malignant Lymphoma.
For subjects with B-CLL
* Documented B-CLL according to the National Cancer Institute Working Group (NCI-WG) criteria.
* Received at least one prior alkylating agent-based regimen and one fludarabine- or pentostatin-containing regimen, but must not have received more than two prior regimens.
* Measurable or assessable disease by NCI-WG criteria.
You may not be if
Known central nervous system involvement of MCL or B-CLL.
Previous treatment with SCH 727965 or other cyclin-dependent kinase inhibitors.
For MCL, previous treatment with bortezomib.
For B-CLL, previous treatment with alemtuzumab.
Known HIV infection.
Known active hepatitis B or C.
Clareo Health | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
